ROBERTA S. KING. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
17
39
.
Keli Wang, Juefang Ding, Xianjing Li, Wenjing Guo, Xingyu Zhu, Yue Su, Luning Sun, Huan Zhou & Li Ding. (2022) Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects. European Journal of Pharmaceutical Sciences 175, pages 106213.
Crossref
Shujun Fu, Feifei Yu, Zhuohan Hu & Tao Sun. (2022) Metabolism-mediated drug–drug interactions – Study design, data analysis, and implications for in vitro evaluations. Medicine in Drug Discovery 14, pages 100121.
Crossref
Hugues Chanteux, Maria Rosa, Claude Delatour, Johan Nicolaï, Eric Gillent, Sylvie Dell’Aiera & Anna-Lena Ungell. (2020) Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes. Drug Metabolism and Disposition 48:9, pages 778-787.
Crossref
Shyam Sundhar Bale & Jeffrey T. Borenstein. (2018) Microfluidic Cell Culture Platforms to Capture Hepatic Physiology and Complex Cellular Interactions. Drug Metabolism and Disposition 46:11, pages 1638-1646.
Crossref
F.P. Guengerich. 2018. Comprehensive Toxicology. Comprehensive Toxicology
54
86
.
Koji Chiba, Keiko Shimizu, Motohiro Kato, Taichi Miyazaki, Takaaki Nishibayashi, Kazuki Terada & Yuichi Sugiyama. (2017) Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans. Journal of Pharmaceutical Sciences 106:9, pages 2695-2703.
Crossref
X. Yang, K. Atkinson & L. Di. (2015) Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method. Drug Metabolism and Disposition 44:3, pages 460-465.
Crossref
Alexander V. LyubimovYuan Chen, Jialin Mao & Adrian J. Fretland. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
26
.
O. B. Usta, W. J. McCarty, S. Bale, M. Hegde, R. Jindal, A. Bhushan, I. Golberg & M. L. Yarmush. (2015)
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of
in-vitro
liver technologies
. TECHNOLOGY 03:01, pages 1-26.
Crossref
Laura J. Kingsley, Gregory L. Wilson, Morgan E. Essex & Markus A. Lill. (2014) Combining Structure- and Ligand-Based Approaches to Improve Site of Metabolism Prediction in CYP2C9 Substrates. Pharmaceutical Research 32:3, pages 986-1001.
Crossref
Shyam Sundhar Bale, Lawrence Vernetti, Nina Senutovitch, Rohit Jindal, Manjunath Hegde, Albert Gough, William J McCarty, Ahmet Bakan, Abhinav Bhushan, Tong Y Shun, Inna Golberg, Richard DeBiasio, O Berk Usta, D Lansing Taylor & Martin L Yarmush. (2014)
In vitro
platforms for evaluating liver toxicity
. Experimental Biology and Medicine 239:9, pages 1180-1191.
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Patricio Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes Georg Bode, Jennifer Bolleyn, Christoph Borner, Jan Böttger, Albert Braeuning, Robert A. Budinsky, Britta Burkhardt, Neil R. Cameron, Giovanni Camussi, Chong-Su Cho, Yun-Jaie Choi, J. Craig Rowlands, Uta Dahmen, Georg Damm, Olaf Dirsch, María Teresa Donato, Jian Dong, Steven Dooley, Dirk Drasdo, Rowena Eakins, Karine Sá Ferreira, Valentina Fonsato, Joanna Fraczek, Rolf Gebhardt, Andrew Gibson, Matthias Glanemann, Chris E. P. Goldring, María José Gómez-Lechón, Geny M. M. Groothuis, Lena Gustavsson, Christelle Guyot, David Hallifax, Seddik Hammad, Adam Hayward, Dieter Häussinger, Claus Hellerbrand, Philip Hewitt, Stefan Hoehme, Hermann-Georg Holzhütter, J. Brian Houston, Jens Hrach, Kiyomi Ito, Hartmut Jaeschke, Verena Keitel, Jens M. Kelm, B. Kevin Park, Claus Kordes, Gerd A. Kullak-Ublick, Edward L. LeCluyse, Peng Lu, Jennifer Luebke-Wheeler, Anna Lutz, Daniel J. Maltman, Madlen Matz-Soja, Patrick McMullen, Irmgard Merfort, Simon Messner, Christoph Meyer, Jessica Mwinyi, Dean J. Naisbitt, Andreas K. Nussler, Peter Olinga, Francesco Pampaloni, Jingbo Pi, Linda Pluta, Stefan A. Przyborski, Anup Ramachandran, Vera Rogiers, Cliff Rowe, Celine Schelcher, Kathrin Schmich, Michael Schwarz, Bijay Singh, Ernst H. K. Stelzer, Bruno Stieger, Regina Stöber, Yuichi Sugiyama, Ciro Tetta, Wolfgang E. Thasler, Tamara Vanhaecke, Mathieu Vinken, Thomas S. Weiss, Agata Widera, Courtney G. Woods, Jinghai James Xu, Kathy M. Yarborough & Jan G. Hengstler. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 87:8, pages 1315-1530.
Crossref
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Steven W. Louie & Magang Shou. 2011. Mass Spectrometry in Drug Metabolism and Disposition. Mass Spectrometry in Drug Metabolism and Disposition
83
149
.
Yuan Chen, Liling Liu, Khanh Nguyen & Adrian J. Fretland. (2011) Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450. Drug Metabolism and Disposition 39:3, pages 373-382.
Crossref
Xavier Boulenc, Wolfgang Schmider & Olivier Barberan. 2011. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
133
160
.
Carl D. Davis & A. David Rodrigues. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
58
.
Roberta S. King. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
24
.
F.P. Guengerich. 2010. Comprehensive Toxicology. Comprehensive Toxicology
41
76
.
Punit H. Marathe & A. David Rodrigues. 2010. Multi-Drug Resistance in Cancer. Multi-Drug Resistance in Cancer
385
403
.
Ramesh B. Bambal & Stephen E. Clarke. 2009. Evaluation of Drug Candidates for Preclinical Development. Evaluation of Drug Candidates for Preclinical Development
55
107
.
Masato Chiba, Yasuyuki Ishii & Yuichi Sugiyama. (2009) Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development. The AAPS Journal 11:2.
Crossref
Magang Shou & Anthony Y. H. Lu. (2009) Antibodies as a Probe in Cytochrome P450 Research. Drug Metabolism and Disposition 37:5, pages 925-931.
Crossref
Makiko Kusama, Kazuya Maeda, Koji Chiba, Akinori Aoyama & Yuichi Sugiyama. (2008) Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data. Pharmaceutical Research 26:4, pages 822-835.
Crossref
Roberta S. King. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
17
40
.
Carl D. Davis & A. David Rodrigues. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
391
447
.
Masakatsu Kotsuma, Hiroyuki Hanzawa, Yoriko Iwata, Kenji Takahashi & Taro Tokui. (2008) Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528. Drug Metabolism and Disposition 36:9, pages 1938-1943.
Crossref
Kuresh A. Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Michelle Griffiths, Amanda Darekar, Ruth Hyland, Odette Fahmi, Susan Hurst, David R. Plowchalk, Jack Cook, Feng Guo & R. Scott Obach. (2008)
Application of CYP3A4
in vitro
data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction
. British Journal of Clinical Pharmacology 65:5, pages 680-692.
Crossref
Timothy W. Harper & Patrick J. Brassil. (2008) Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates. The AAPS Journal 10:1, pages 200-207.
Crossref
María José Gómez-Lechón, José Vicente Castell & María Teresa Donato. (2007) Hepatocytes—the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chemico-Biological Interactions 168:1, pages 30-50.
Crossref